STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] CRYO CELL INTERNATIONAL INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cryo-Cell International (CCEL) announced it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company stated that future dividends may or may not be paid, with decisions driven by financial performance, capital requirements, and strategic priorities.

This update signals a pause in cash distributions for Q4 FY2025 and places emphasis on deploying resources based on operating needs and strategic plans. The company’s stance leaves flexibility for future payouts if conditions align with its financial and strategic criteria.

Positive
  • None.
Negative
  • None.

Insights

CCEL pauses Q4 FY2025 dividend; future payouts remain discretionary.

Cryo-Cell will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company notes that future dividends may or may not occur and will depend on financial performance, capital requirements, and strategic priorities.

This move preserves cash that would otherwise be distributed, with the actual benefit hinging on operating needs and investment opportunities. The announcement frames dividends as a flexible tool rather than a fixed commitment.

The next meaningful indicator will be any subsequent disclosure outlining dividend decisions tied to future periods. Subsequent filings may provide how performance and capital plans shape payout choices.

false000086269200008626922025-11-122025-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

 

 

CRYO-CELL INTERNATIONAL, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40767

22-3023093

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

700 Brooker Creek Blvd.

Suite 1800

 

Oldsmar, Florida

 

34677

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 813 749-2100

 

 

 

,

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

CCEL

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

Cryo-Cell International, Inc. ("Cryo-Cell") will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. Cryo-Cell may or may not pay a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Cryo-Cell International, Inc.

 

 

 

 

Date:

November 12, 2025

By:

/s/ David Portnoy

 

 

 

David Portnoy, Chairman and Co-CEO

 


FAQ

What did Cryo-Cell (CCEL) announce regarding its Q4 FY2025 dividend?

Cryo-Cell stated it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025.

Will Cryo-Cell (CCEL) pay dividends in future periods?

The company said it may or may not pay dividends in future periods, depending on financial performance, capital requirements, and strategic priorities.

Why did Cryo-Cell (CCEL) change its dividend approach?

The company indicated dividend decisions will be based on financial performance, capital requirements, and strategic priorities.

Does this announcement affect only Q4 FY2025 for Cryo-Cell (CCEL)?

Yes, the company specifically noted no quarterly cash dividend for the fourth quarter of fiscal 2025.

Where is Cryo-Cell (CCEL) listed and what is its ticker?

Cryo-Cell’s common stock trades on the NYSE American under the ticker CCEL.
Cryo-Cell Intl Inc

NYSE:CCEL

CCEL Rankings

CCEL Latest News

CCEL Latest SEC Filings

CCEL Stock Data

32.95M
4.27M
40.48%
12.37%
0.18%
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
OLDSMAR